143 related articles for article (PubMed ID: 27849360)
1. Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity.
Elfers CT; Roth CL
Endocrinology; 2017 Jan; 158(1):41-55. PubMed ID: 27849360
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061.
Burkey BF; Hoglen NC; Inskeep P; Wyman M; Hughes TE; Vath JE
J Pharmacol Exp Ther; 2018 May; 365(2):301-313. PubMed ID: 29491038
[TBL] [Abstract][Full Text] [Related]
3. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732.
Kim YM; An JJ; Jin YJ; Rhee Y; Cha BS; Lee HC; Lim SK
J Mol Endocrinol; 2007 Apr; 38(4):455-65. PubMed ID: 17446235
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.
Proietto J; Malloy J; Zhuang D; Arya M; Cohen ND; de Looze FJ; Gilfillan C; Griffin P; Hall S; Nathow T; Oldfield GS; O'Neal DN; Roberts A; Stuckey BGA; Yue D; Taylor K; Kim D
Diabetologia; 2018 Sep; 61(9):1918-1922. PubMed ID: 29992370
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial.
Kim DD; Krishnarajah J; Lillioja S; de Looze F; Marjason J; Proietto J; Shakib S; Stuckey BGA; Vath JE; Hughes TE
Diabetes Obes Metab; 2015 Jun; 17(6):566-572. PubMed ID: 25732625
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity.
Shoemaker A; Proietto J; Abuzzahab MJ; Markovic T; Malloy J; Kim DD
Diabetes Obes Metab; 2017 Aug; 19(8):1165-1170. PubMed ID: 28261955
[TBL] [Abstract][Full Text] [Related]
8. Hyperphagia in male melanocortin 4 receptor deficient mice promotes growth independently of growth hormone.
Tan HY; Steyn FJ; Huang L; Cowley M; Veldhuis JD; Chen C
J Physiol; 2016 Dec; 594(24):7309-7326. PubMed ID: 27558671
[TBL] [Abstract][Full Text] [Related]
9. Aspergillus, angiogenesis, and obesity: the story behind beloranib.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2015 Mar; 53(3):13-6. PubMed ID: 25751824
[TBL] [Abstract][Full Text] [Related]
10. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women.
Hughes TE; Kim DD; Marjason J; Proietto J; Whitehead JP; Vath JE
Obesity (Silver Spring); 2013 Sep; 21(9):1782-8. PubMed ID: 23512440
[TBL] [Abstract][Full Text] [Related]
11. Chronic blockade of the melanocortin 4 receptor subtype leads to obesity independently of neuropeptide Y action, with no adverse effects on the gonadotropic and somatotropic axes.
Raposinho PD; Castillo E; d'Alleves V; Broqua P; Pralong FP; Aubert ML
Endocrinology; 2000 Dec; 141(12):4419-27. PubMed ID: 11108250
[TBL] [Abstract][Full Text] [Related]
12. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
[TBL] [Abstract][Full Text] [Related]
13. Introduction of a high-energy diet acutely up-regulates hypothalamic cocaine and amphetamine-regulated transcript, Mc4R and brown adipose tissue uncoupling protein-1 gene expression in male Sprague-Dawley rats.
Archer ZA; Rayner DV; Duncan JS; Bell LM; Mercer JG
J Neuroendocrinol; 2005 Jan; 17(1):10-7. PubMed ID: 15720470
[TBL] [Abstract][Full Text] [Related]
14. Activation of hypothalamic NPY, AgRP, MC4R, AND IL-6 mRNA levels in young Lewis rats with early-life diet-induced obesity.
Stofkova A; Skurlova M; Kiss A; Zelezna B; Zorad S; Jurcovicova J
Endocr Regul; 2009 Jul; 43(3):99-106. PubMed ID: 19817504
[TBL] [Abstract][Full Text] [Related]
15. The mahoganoid mutation (Mgrn1md) improves insulin sensitivity in mice with mutations in the melanocortin signaling pathway independently of effects on adiposity.
Phan LK; Chung WK; Leibel RL
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E611-20. PubMed ID: 16638826
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.
Kumar KG; Sutton GM; Dong JZ; Roubert P; Plas P; Halem HA; Culler MD; Yang H; Dixit VD; Butler AA
Peptides; 2009 Oct; 30(10):1892-900. PubMed ID: 19646498
[TBL] [Abstract][Full Text] [Related]
17. Food motivated behavior of melanocortin-4 receptor knockout mice under a progressive ratio schedule.
Vaughan C; Moore M; Haskell-Luevano C; Rowland NE
Peptides; 2006 Nov; 27(11):2829-35. PubMed ID: 16930774
[TBL] [Abstract][Full Text] [Related]
18. Hypothalamic pro-opiomelanocortin gene delivery ameliorates obesity and glucose intolerance in aged rats.
Li G; Zhang Y; Wilsey JT; Scarpace PJ
Diabetologia; 2005 Nov; 48(11):2376-85. PubMed ID: 16205885
[TBL] [Abstract][Full Text] [Related]
19. The hyperleptinemia and ObRb expression in hyperphagic obese rats.
Han Y; Joe Y; Seo E; Lee SR; Park MK; Lee HJ; Kim DK
Biochem Biophys Res Commun; 2010 Mar; 394(1):70-4. PubMed ID: 20171169
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibition reduces food intake and weight gain and improves glucose tolerance in melanocortin-4 receptor deficient female rats.
Mul JD; Seeley RJ; Woods SC; Begg DP
Physiol Behav; 2013 Sep; 121():43-8. PubMed ID: 23416175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
